Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C] HRS-5965 in Healthy Chinese Subjects
NCT06567392Phase 1Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-5965 in complement mediated glomerular disease, sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoints: Total radioactive recovery rate in urine and feces, Cumulative total radioactive recovery rate in urine and feces and 7 more. Started Sep 2024; status: completed.
02
Drugs
HRS-5965
03
Conditions
complement mediated glomerular disease
Beyond the preview
Go deeper on NCT06567392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567392.